PAS
AZN icon

Park Avenue Securities’s AstraZeneca AZN Stock Holding History

Park Avenue Securities’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.1M Buy
53,856
+1,073
+2% +$202K 0.06% 238
2026
Q1 		$10.2M Sell
52,783
-610
-1% -$118K 0.08% 194
2025
Q4 		$9.82M Buy
53,393
+1,455
+3% +$255K 0.08% 190
2025
Q3 		$7.97M Buy
51,938
+7,101
+16% +$1.07M 0.06% 233
2025
Q2 		$6.27M Buy
44,837
+347
+0.8% +$48.6K 0.06% 241
2025
Q1 		$6.54M Buy
44,490
+5,834
+15% +$844K 0.08% 171
2024
Q4 		$5.07M Buy
38,656
+7,355
+23% +$1.03M 0.05% 241
2024
Q3 		$4.88M Sell
31,301
-3,394
-10% -$548K 0.05% 221
2024
Q2 		$5.41M Buy
34,695
+8,080
+30% +$1.22M 0.07% 201
2024
Q1 		$3.61M Buy
26,615
+283
+1% +$37.5K 0.05% 255
2023
Q4 		$3.55M Buy
26,332
+3,813
+17% +$496K 0.05% 229
2023
Q3 		$3.05M Buy
22,519
+2,391
+12% +$327K 0.05% 238
2023
Q2 		$2.88M Buy
20,128
+12
+0.1% +$1.77K 0.05% 240
2023
Q1 		$2.79M Buy
20,116
+4,416
+28% +$594K 0.05% 227
2022
Q4 		$2.13M Buy
15,700
+1,283
+9% +$161K 0.04% 296
2022
Q3 		$1.58M Buy
14,417
+3,302
+30% +$419K 0.03% 315
2022
Q2 		$1.47M Buy
11,115
+1,661
+18% +$218K 0.03% 339
2022
Q1 		$1.25M Buy
9,454
+669
+8% +$80.2K 0.02% 402
2021
Q4 		$1.02M Sell
8,785
-641
-7% -$75.4K 0.02% 466
2021
Q3 		$1.13M Buy
9,426
+3,569
+61% +$415K 0.02% 373
2021
Q2 		$702K Buy
5,857
+1,376
+31% +$151K 0.01% 518
2021
Q1 		$446K Buy
4,481
+910
+25% +$91.5K 0.01% 623
2020
Q4 		$357K Buy
3,571
+1,432
+67% +$152K 0.01% 612
2020
Q3 		$234K Sell
2,139
-251
-11% -$27.9K 0.01% 664
2020
Q2 		$253K Buy
+2,390
New +$247K 0.01% 565

Other funds holding AZN

RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
CDDEC
Caisse Des Depots Et Consignations Paris, France $5.91B AUM 35.65% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $9.71B AUM 37.32% 1-Year Est. Return
MIF
Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return
ZIC
ZWJ Investment Counsel Atlanta, Georgia $3.09B AUM 39.43% 1-Year Est. Return

Park Avenue Securities's AZN Position: Q2 2026 in Review

Park Avenue Securities increased its AstraZeneca (AZN) stake by 2% in Q2 2026, buying an estimated $202K and bringing the position to 53,856 shares worth $10.1M. The position accounts for 0.06% of the portfolio, ranked #238.

Park Avenue Securities first reported a position in AZN in Q2 2020 and has held it in 25 quarters since. The position peaked at $10.2M in Q1 2026. 443 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Park Avenue Securities held 53,856 shares of AstraZeneca worth $10.1M as of Q2 2026.
  • Park Avenue Securities bought 1,073 AstraZeneca shares in Q2 2026, an estimated $202K.
  • AstraZeneca made up 0.06% of Park Avenue Securities's portfolio in Q2 2026, its #238 holding.
  • Park Avenue Securities first reported a position in AstraZeneca in Q2 2020 and has held it in 25 quarters since.
  • Park Avenue Securities's AstraZeneca position peaked at $10.2M in Q1 2026.
  • 443 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Park Avenue Securities's 13F filing for Q2 2026, filed 20 Jul 2026.